Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
Open accessThe DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs), namely nausea, vomiting, diarrhoea and/or constipation. To minimize their severity and duration, healthcare providers (HCPs) and patients must be aware of appropriate measures to follow while undergoing treatment. An expert panel comprising endocrinologists, nephrologists, primary care physicians, cardiologists, internists and diabetes nurse educators convened across virtual meetings to reach a consensus regarding these compelling recommendations. Firstly, specific guidelines are provided about how to reach the maintenance dose and how to proceed if GI AEs develop during dose-escalation. Secondly, specific directions are set about how to avoid/minimize nausea, vomiting, diarrhoea and constipation symptoms. Clinical scenarios representing common situations in daily practice, and infographics useful to guide both HCPs and patients, are included. These recommendations may prevent people with T2D and/or obesity from withdrawing from GLP-1 RAs treatment, thus benefitting from their superior effect on glycaemic control and weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These gastrointestinal adverse events are poorly documented in the literature due to their low frequency [6].”
From Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis (2025) · cites this paper as [6]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial gastrointestinal side effects were reported by approximately 30% of participants, which were generally mild to moderate in severity and significantly diminished during sustained treatment achieved through dose titration, resulting in a discontinuation rate of less than 8% [87].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These are more likely to occur within the first weeks of initiation of therapy and with dose escalation. Side effects tend to decrease in frequency and severity with continuation of a stable dose [40].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Higher doses are more likely to provoke these adverse symptoms, indicating a dose‐dependent relationship [40].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because dietary lipids act synergistically with GLP-1 to inhibit gastric emptying, reducing fat load per meal is a physiologically plausible and commonly recommended strategy to reduce postprandial nausea and fullness during GLP-1 RA titration, although randomized dietary-modification trials specifically in GLP-1-treated cohorts are lacking [66,67].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [66]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global clinical measure of fitness and frailty in elderly people
Rockwood, K. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050051 · Cited by 8,968 · cited 1×
“The Clinical Frailty Scale may sometimes be useful to guide dose adjustment [75].”
MethodLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“CKD increases the risk of GLP-1 RA-associated diarrhoea, with symptoms being more severe with albuminuria [84].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 2×
“Although reported data from trials and real-world series do not show definitive differences between GLP-1 RAs in terms of tolerability (Table 1), there are studies claiming that the tolerability profile may vary between differe t compounds [1,33,39].”
BackgroundResultSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 1×
“Of note, a recent meta-analysis encompassing those clinical trials focused on the cardiovascular safety of GLP-1 RAs found significant reductions in MACE3 (a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), hospitalization for heart failure and progression of chronic kidney di…”
ResultDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2021.11.014 · Cited by 566 · cited 1×
“Sarcopenia risk must be assessed before and during GLP-1 RA treatment since the sharp weight loss in the elderly may be in part at the expense of lean mass [80,81].”
Background
Research works printed but not linked: 2
- 2010, Liraglutide in the treatment of type 2 diabetes: Recommendations for better patients’ selection from a multidisciplinary approach, Av. Diabetol., 26, 226
- 2014, Pancreatitis aguda severa y precoz por liraglutide, Arch. Med. Int., 36, 119
Cited by
Items 301–355 of 355
Tan, A. S. H., Saafan, T. S. M., Ashoush, F., & Mahawar, K. K. (2026) · World Journal of Clinical Cases · doi:10.12998/wjcc.121701
Practical Considerations for the Use of Oral Glucagon-like Peptide-1 Receptor Agonist in India
Ashraf, H., Bakshi, S., Ekatpure, H., Kumar, N. S. P., Acharyya, M., Reddy, J. N., Ghosh, J., Goel, A., Chaudhary, R., Saini, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_25_26
Kapan, A., Moser, O., Felsinger, R., & Waldhoer, T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1864209 · Cited by 1
Anterior Cutaneous Nerve Entrapment Syndrome From Glucagon-Like Peptide-1 Receptor Agonist Injection
Singh, N., Chaparro, E., Shapiro, J. M., & Husu, E. N. (2026) · ACG Case Reports Journal · doi:10.14309/crj.0000000000002168
“…with the use of GLP-1 agonists, with the most common being nausea, vomiting, gastro-paresis, diarrhea, constipation, and pancreatitis (less likely) 9 ; but in this case, administration of subcutaneous GLP-1 agonist injections coincided with the onset of ACNES, possibly by irritation of the…”
Singh, A. K., Yadav, D., & Singh, M. P. (2026) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_1343_25
“[87] Nutritional counseling plays a pivotal role.”
GLP-1 Receptor Agonists beyond Glycemic Control: Physiology and Pharmacological Evidence
Amate, P. (2026) · Open Journal of Pharmacology and Pharmacotherapeutics · doi:10.17352/ojpp.000029
Innovative Diabetes Care and Education Services to Improve Outcomes in Youth-Onset Type 2 Diabetes
Allen, R. A. (2026) · ADCES in Practice · doi:10.1177/2633559x261433807
Sensitive issues of the incretin-based therapy
BAKULIN, I., Sukhomlinova, I. M., Lebedeva, Y., & BELOUSOV, A. (2026) · Медицинский вестник МВД · doi:10.52341/20738080_2026_142_3_25
Brunetti, K., Fassari, B., Catalani, E., Galletti, G., Quondam, S. D., Mocciaro, E., Giovarelli, M., Palma, C. D., Perrotta, C., Clementi, E., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119735
Matsuo, Y., Okada, A., Sakamoto, T., & Yasunaga, H. (2026) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70164
“Even in the absence of such specific awareness, the well-known gastrointestinal side-effect profile of GLP-1RAs [ 34 ] may have led physicians to discontinue them after the bowel obstruction/ileus event.”
Joshi, S., Misra, A., Mithal, A., Saboo, B., Seshadri, K., Chowdhury, S., Bantwal, G., Sethi, B. K., Kesavadev, J., Bhattacharya, A. D., et al. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100296
“The underlying cause of these side effects may vary, and the side effects may further increase with higher dosage, indicating a dose – response relationship [32].”
NEW ERA IN DIABETES AND OBESITY TREATMENT - THE EFFECTS OF GLP-1R, GIPR AND GCGR TRIAGONISTS
Duliński, M., Gofron, K. K., Kaźmierkiewicz, K., Spychalska, W., Piotrowicz, E., Witowicz, F., Glińska, J., Krawczyk, A., Waldon, W., & Sumlet, P. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6156
Abegaz, T. M., Frietze, G. A., & Das, A. B. (2026) · AI in Medicine · doi:10.3390/aimed1030019
“These factors are clinically relevant, as temporary discontinuation and reinitiation of GLP-1 RA therapy are common in response to adverse effects and may influence ADR occurrence [19].”
Shegena, E. A., Kiflu, M., Ahmed, M. B., Bhagavathula, A. S., & Abegaz, T. M. (2026) · Obesity Reviews · doi:10.1111/obr.70200
Liang, J., Bo, L., Miao, X., Guo, X., Xu, J., He, J., & Ye, X. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-026-01190-4
“Available evidence indicates that the predominant safety signals involve gastrointestinal disturbances, most commonly nausea, vomiting, and diarrhea [11–13].”
Chabassier, A., Vittrant, B., Binon, P., Scornet, E., & Josse, J. (2026) · Mayo Clinic Proceedings Digital Health · doi:10.1016/j.mcpdig.2026.100375 · Cited by 1
Salgado, T. M., Amayreh, R., Alshahawey, M., Musselman, K. T., Buffington, T. M., Hyder, H., Jones, R. M., & Dixon, D. L. (2026) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70263
“These findings are consistent with broader literature on barriers to newer diabetes therapies, where fear of side effects and reluctance to initiate injectable medications limit adoption even when patients are clinically appropriate candidates [42, 43].”
Kim, T., Seo, J., Kang, S., Kim, H. K., Lee, B., Lee, J., & Go, G. (2026) · Food Science and Biotechnology · doi:10.1007/s10068-026-02259-w
Evaluating the use of GLP-1 receptor agonists in Wolfram syndrome patients
Lee, L. A., Tang, A. F., Asako, A., Ning, S., Reed, H. A., Duncan, E., Lugar, H. M., Hoekel, J., Marshall, B. A., Hershey, T. G., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1847818
Changement dans la prise en charge de l’obésité : vision du clinicien
Montastier, É. (2026) · Biologie Aujourd hui · doi:10.1051/jbio/2026002
Cardamone, K., Byham-Gray, L. D., Sackey, J. D., & Brody, R. A. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156432
Balasubaramaniam, V., Scobie, M., O’Kane, M. P. M., Graham, Y., Robertson, A. G., & Mahawar, K. K. (2026) · Nutrients · doi:10.3390/nu18162643
“It can be hypothesised from this indirect evidence that without structured guidance, patients may lose weight while failing to meet protein, fibre, micronutrient and hydration requirements [10,29,33,34,37,63].”
InfluentialJi, L., Chen, L., Cheng, Z., Lu, Y., Yang, Y., Fu, F., Zhu, Y., Jin, L., & Kloer, I. M. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01908-x
Li, J., Wen, J., Zheng, H., Quan, C., Bi, J., Yang, Y., Zhang, J., & Shen, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902260
Wang, T., & Shiyanbola, O. O. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01639-0
“Clinicians may provide education about expected adverse effects, guidance during dose escalation, and counsel - ing on realistic weight trajectories to help patients navigate early treatment challenges [36].”
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
“Most GI adverse effects arise during the dose-escalation period and tend to subside once a maintenance dose is reached, suggesting physiological adaptation [97].”
Beyond One-Size-Fits-All: Individually Tailored Dietary Interventions in Modern Obesity Care
Cozma-Petruț, A. P., Gherghel, M., Banc, R., Tișa, I. B., Stanciu, O., Coldea, T. E., Mudura, E., Miere, D., & Filip, L. A. (2026) · Nutrients · doi:10.3390/nu18162691 · Cited by 1
“Higher therapeutic doses have also been associated with a greater likelihood of gastrointestinal intolerance [161].”
InfluentialFernando, S., Zhao, J., Josloff, K., Zubair, N., Desai, A., Shivashankar, R., Kozuch, P. L., Choudhary, C., Lichtenstein, G. R., & Sehgal, P. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2026.1864456 · Cited by 1
“If symptoms persist, providers can also consider spacing out the GLP-1RA dosing by greater than 7 days (41).”
L’integrazione tra dieta e farmaci nell’era delle nuove terapie per l’obesità
Vitacolonna, E., Masi, D., & Watanabe, M. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01855-6
“È quindi essenziale in-tegrare nella TMN indicazioni specifiche per migliorare la tollerabilità e l’aderenza [6, 12].”
Yuce, T. K., Radwan, R. M., Lee, Y. A., Holler, E., Dai, H., He, X., Huang, Y., Guo, Y., Bian, J., & Guo, J. (2026) · Obesity · doi:10.1002/oby.70280
Saeed, Z. I., Donnelly-Boylen, M., Hammershøy, L., Bilal, I., ROLIN, A., Micheelsen, A., Knop, F. K., LAURSEN, J. V., & Aroda, V. R. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100328
RetractedLee, C.-M., Kim, J.-Y., Shim, J.-H., & Cho, G.-W. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2928-5204
Jonnalagadda, A., Lowry, W. P., Pathak, G. N., Choi, E., Zhou, A. E., & Grant-Kels, J. M. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.09.002
Lim, E., Cheng, N. C. L., & Lim, C. E. D. (2026) · Nutrition & Food Science · doi:10.1108/nfs-05-2026-0239
The Dark Side of GLP-1 Receptor Agonists: Risks and Adverse Events
Nawal, C. L., Saini, H. L., Rankawat, G., & Chejara, R. S. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1655
Seo, J., Choi, S., Kim, N., Kim, H., & Lim, H.-S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1846164
The Intersection of Diabetes and Gastrointestinal Health: A Narrative Review
Bi’aragh, S. H., Afsahi, R., Nasab, A. E., Khani, M., Rasouli, K., Ahangar, M. H., Soltani, A. S., & Pourahmad, R. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02712-1
“Their mechanisms, therapeutic benefits, and GI effects require careful balancing to opti - mize clinical outcomes [75].”
Mahmood, T., Myrtziou, I., & Kanakis, I. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02089-x
“Type 2 diabetes (T2D) is progres - sive and often requires sequential treatment intensification as glycaemic control deteriorates [ 3].”
InfluentialAlkhateeb, F. S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02716-x
“Tolerability, treatment interruptions, drug availability, and affordability therefore need to be considered alongside efficacy when estimating the benefit a patient is likely to achieve outside a trial [61, 62].”
Brancato, D., Borretta, G., Chianelli, M., Disoteo, O., Grasso, M., Grimaldi, F., Guastamacchia, E., Muratori, F., Oleandri, S., Orio, M., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1907270
Sibal, R., Balamurugan, G., Aradaib, M., Graham, Y. N. H., & Mahawar, K. K. (2026) · Medicina · doi:10.3390/medicina62101916
Migraine and Obesity: From Shared Mechanisms to Therapeutic Strategies
Waliszewska‐Prosół, M., Raffaelli, B., Pellesi, L., Raggi, A., Onan, D., Marschollek, K., Montisano, D. A., Tana, C., & Martelletti, P. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-01050-7 · Cited by 2
Farinha, R. B. A., Silva, L. H., de Noronha, M. E. C., Pinheiro, T. D. S., & Ramos, T. B. (2026) · Journal of Consumer Health on the Internet · doi:10.1080/15398285.2026.2742794
Efsubaglutide Alfa: A Comprehensive Pharmacological Review
Zheng, H., Yan, R., Jiang, F., Li, Y., Prud’homme, G. J., & WANG, Q. (2026) · Clinical Pharmacokinetics · doi:10.1007/s40262-026-01713-6
GLP‐1 receptor agonists in Alzheimer's disease and MCI: a meta‐analysis
Siqueira, R. G. P., Ranalli, C., Yılmaz, D., Silva, M., Maltez, B. R. P., Berton, G. G., & Cummings, J. L. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70334
“30 A weight-loss effect that may be beneficial in obesity or type 2 diabetes should not be assumed tobeneutralinsymptomaticAD,andthissideeffectwarrantsvigilance”
Dakin, C. A., Beaumont, J. D., & O’Hara, B. (2026) · Obesity Reviews · doi:10.1111/obr.70245
Belalcazar, L. M., Gao, D., Modi, S., Meer, A., & Kuo, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71448
Schwartzberg, E., Azran, C., Diker‐Cohen, T., Shani, S., & Dotan, I. (2026) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2026.100867
“25 • Constipation: A focus on fluid and fiber intake is paramount.”
Dose-response profiles in incretin and multi-agonist obesity pharmacotherapy
Yousefian, M., & Baharmast, M. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102947
Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies
Kounatidis, D. C., Vallianou, N. G., Kouveletsou, M., Kontrafouri, P., Stamatopoulos, V., Rebelos, E., Diakoumopoulou, E., & Dalamaga, Μ. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00770-z
“Loperamide or selected probiotics may be considered for persistent diarrhea, while stool softeners or osmotic laxatives may be used for refractory constipation [89].”
Berikkhanova, K., Inuwa, I., Sultan, Y., Berikkhanov, N., Rakhimova, S., & Akilzhanova, A. R. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15208190
“Nevertheless, persistent or severe gastrointestinal symptoms can https://doi.org/10.3390/jcm15208190 impair treatment adherence and are an important cause of dose interruption or permanent discontinuation [84,85].”
InfluentialCassano, D., Fernández, G., Cornejo, M. P., Sheybani-Deloui, S., Aguggia, J. P., Cantel, S., Fehrentz, J., Habib, A. M., Rolland, L., Ravier, M. A., et al. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124754
Kumbhare, S. V., Pedroso, I., Sinha, R., & Almonacid, D. E. (2026) · Frontiers in Microbiomes · doi:10.3389/frmbi.2026.2016564
Makuc, J., & Janić, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15218295
Serebrova, S. Y., Gorodetskaya, G. I., Lazareva, N. B., Demchenkova, E. Y., Еременко, Н. Н., Bogdanova, N. G., & Zhuravleva, M. V. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-425
Metadata
- Authors
- Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á.
- Affiliations
- Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain
- Department of Endocrinology and Nutrition, Hospital Universitario Torrecárdenas, 04009 Almería, Spain
- Department of Internal Medicine, University Hospital of Badajoz, 06080 Badajoz, Spain
- Hospital Universitario La Paz (ES)
- Health Centre Casco Antiguo Cartagena, Primary Care Research Group, Biomedical Research Institute of Murcia (IMIB), 30201 Cartagena, Spain
- Department of Internal Medicine, Costa del Sol Hospital, 29603 Marbella, Spain
- Hospital Clínico Universitario de Valencia (ES)
- Madrid Health Service (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Universitat de València (ES)
- Department of Endocrinology and Nutrition, San Carlos Clinical Hospital, Health Research Institute of the San Carlos Clinical Hospital (IDISSC), 28040 Madrid, Spain
- Corresponding author
- Górriz, José Luis
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2022-12-24
- Volume
- 12
- Issue
- 1
- Pages
- 145
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC9821052
- OpenAlex
- W4313260808
- Cited by
- 358
- References
- 83
- Citations by year
- 2026: 137 · 2025: 140 · 2024: 63 · 2023: 18
- FWCI
- 40.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
- Funders
- Novo-Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, gastrointestinal adverse effects, nausea, vomiting, diarrhea, constipation, type 2 diabetes, obesity, dose escalation, maintenance dose, treatment discontinuation, glycemic control, weight loss, patient education
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.